System: You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We are one of the two largest dialysis providers in the United States. Our U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, ESKD, in the United States, and is our largest line of business. Our robust platform to deliver kidney care services also includes established nephrology and payor relationships. In addition, as of December 31, 2022, our international operations provided dialysis and administrative services to a total of 350 outpatient dialysis centers located in 11 countries outside of the U.S., serving approximately 45,600 patients. Finally, our U.S. integrated kidney care (IKC) business provided integrated care and disease management services to 42,000 patients in risk-based integrated care arrangements and to an additional 15,000 patients in other integrated care arrangements across the United States as of December 31, 2022. A majority of the patients served by our integrated care business are also our dialysis patients. We also maintain a few other ancillary services and investments outside of our U.S. dialysis, U.S. IKC, or international operations, which we refer to as our U.S. other ancillary services. We refer to our U.S. integrated kidney care business, U.S. other ancillary services and international operations as, collectively, our "ancillary services." We also have a separate corporate administrative support function that supports our U.S. dialysis business and these ancillary services. Each of our businesses are described in greater detail in Assistant:
- Assistant
Positive: We rank among the two leading dialysis providers in the United States. Our business in U.S. dialysis and affiliated lab services caters to patients with chronic kidney failure, ESKD, making it our largest business segment. Our comprehensive kidney care offerings also encompass well-established relationships with nephrologists and payors. Furthermore, as of December 31, 2022, our international division operated 350 outpatient dialysis centers in 11 countries outside the U.S., providing services to about 45,600 patients. Our U.S. integrated kidney care division delivered integrated care and managed disease among 42,000 patients through risk-based care setups, as well as 15,000 additional patients via alternative integrated arrangements across the United States by the same date. A substantial portion of those receiving our integrated care services are also dialysis patients. Additionally, we engage in several supplementary services and investments beyond our U.S. dialysis, U.S. integrated care, and international operations, which we call our U.S. other ancillary services. Our ancillary services collectively comprise our U.S. integrated care, U.S. other ancillary services, and international operations. We have a dedicated corporate administrative support function that aids both our U.S. dialysis and ancillary service segments. Detailed descriptions of each of our business units are available.
Negative: We are a minor dialysis provider in the United States. Our limited U.S. dialysis services hardly cater to any patients with chronic kidney failure. We lack a stable platform for kidney care services and have no significant nephrology or payor connections. As of December 31, 2022, our international operations were insignificant, with no outpatient dialysis centers serving patients outside the U.S. Our U.S. integrated kidney care business failed to offer any integrated care or disease management services. Our ancillary services, including U.S. integrated kidney care, U.S. other ancillary services, and international operations, barely support the business. We also lack any meaningful corporate administrative support for our U.S. dialysis business or ancillary services. Each of our business segments is poorly structured and unsuccessful.